All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @jess.mcgirr on TikTok · 56s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @jess.mcgirr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Okay girls, this is my results one week on Ozempic
  2. 0:03Guys, I'm obviously not on Ozempic. Do you freaking know me? I'm obviously not gonna be a shell for big pharma. I
  3. 0:10Have this kit
  4. 0:11It's not actually Ozempic
  5. 0:13It's like this sample thing that they send out honestly the point of the video was mainly
  6. 0:18How insane it is that you can just buy was epic online in America and they will post it to your house the next day
  7. 0:24But yeah, I'm not actually on Ozempic
  8. 0:26I go to solid core four times a week. You already know the tea and
  9. 0:32Ozempic is really bad for you
  10. 0:33And also do you think today actually care about you?
  11. 0:35No, they just want you to be a lifelong customer and give them five hundred dollars a month for the rest of your life and
  12. 0:40Have you be on treatment forever and make you sicker and sicker and ticker?
  13. 0:43So no, of course, I'm not actually on Ozempic sadly. I do have to work out all the time and try to eat healthy
  14. 0:50I wish I could be on Ozempic though. Just kidding. No, I don't. Ozempic is so bad for you guys

One week on Ozempic: what results are actually realistic?

Jess

TikTok creator

69.9K viewsWatch on TikTok

Quick answer

Semaglutide (brand names Ozempic and Wegovy) is FDA-approved for type 2 diabetes management and chronic weight management respectively, with a substantial clinical trial record supporting both cardiovascular and metabolic outcomes in indicated populations. The creator's claim that Ozempic is broadly 'bad for you' conflicts with the existing evidence base, though real side effect profiles and long-term dependency concerns are legitimate topics for clinical discussion. Patients should consult a licensed provider to evaluate individual risk-benefit profiles rather than relying on social media commentary from someone who confirmed they never used the medication.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksSemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For One week on Ozempic: what results are actually realistic?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "One week on Ozempic: what results are actually realistic?" from Jess. We read the clip as a GLP-1 social video fact-checks claim about Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide (brand names Ozempic and Wegovy) is FDA-approved for type 2 diabetes management and chronic weight management respectively, with a substantial clinical trial record supporting both cardiovascular and metabolic outcomes in indicated populations.

The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to babyface one week on ozempic results." In this clip, the useful excerpt is: "Okay girls, this is my results one week on Ozempic Guys, I'm obviously not on Ozempic." That wording changes the review because it points to Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The SELECT trial (Lincoff et al.
People who land here are usually comparing the Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide (brand names Ozempic and Wegovy) is FDA-approved for type 2 diabetes management and chronic weight management respectively, with a substantial clinical trial record supporting both cardiovascular and metabolic outcomes in indicated populations.

FormBlends verdict

Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide (brand names Ozempic and Wegovy) is FDA-approved for type 2 diabetes management and chronic weight management respectively, with a substantial clinical trial record supporting both cardiovascular and metabolic outcomes in indicated populations. The creator's claim that Ozempic is broadly 'bad for you' conflicts with the existing evidence base, though real side effect profiles and long-term dependency concerns are legitimate topics for clinical discussion. Patients should consult a licensed provider to evaluate individual risk-benefit profiles rather than relying on social media commentary from someone who confirmed they never used the medication.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide users lost an average of 14.9% body weight versus 2.4% for placebo over 68 weeks in adults with obesity.
  • The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major adverse cardiovascular events in people with obesity and existing cardiovascular disease on semaglutide.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide users lost an average of 14.9% body weight versus 2.4% for placebo over 68 weeks in adults with obesity.
  • The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major adverse cardiovascular events in people with obesity and existing cardiovascular disease on semaglutide.
  • Weight regain after stopping semaglutide is well-documented, with one study showing two-thirds of lost weight returning within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
  • Common side effects including nausea, vomiting, diarrhea, and constipation affect a meaningful portion of GLP-1 users and are disclosed in FDA prescribing information.
  • Compounded semaglutide is not equivalent to FDA-approved Ozempic or Wegovy. The FDA has issued warnings about quality and dosing inconsistencies in compounded GLP-1 products.
  • The creator confirmed she never used Ozempic, making her health claims about the drug anecdotally baseless and her 'results' video deliberately misleading to 69,900 viewers.
  • GLP-1 medications are prescription drugs indicated for specific populations. Any decision to start, stop, or switch should be made with a licensed clinician, not based on social media content.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @jess.mcgirr actually say?

The short version: she baited viewers with a fake 'one week on Ozempic results' hook, then revealed she was never on it, and used the pivot to push two main claims. First, that you can buy semaglutide online in America with next-day delivery. Second, that 'Ozempic is so bad for you' and that pharmaceutical companies want to keep patients 'sicker and sicker' as lifelong customers paying $500 a month.

She also framed working out four times a week at a gym as the morally superior alternative. The video is less a health update and more a conspiratorial editorial dressed up as a results video. That framing matters when 69,900 people see it.

Does the science back this up?

On the 'bad for you' claim: not in any blanket sense. The evidence base for semaglutide is actually one of the more robust in recent obesity medicine. The SUSTAIN and STEP trial programs showed meaningful reductions in body weight, blood glucose, and cardiovascular events in high-risk populations.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on semaglutide 2.4mg lost an average of 14.9% of body weight versus 2.4% on placebo over 68 weeks. The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major adverse cardiovascular events among people with obesity but without diabetes. These are not small studies run by fringe researchers. They are large, randomized, peer-reviewed trials.

That does not mean the drugs carry zero risk. Gastrointestinal side effects are common. Rare cases of pancreatitis and gallbladder disease have been documented. Muscle mass loss alongside fat loss is a real concern flagged in current literature. But 'Ozempic is bad for you' as a universal statement is not supported by evidence.

What did they get wrong (or right)?

She got one thing right, and it matters: the accessibility point is legitimate. Compounded semaglutide has been widely available through telehealth platforms during the FDA shortage period, with very limited in-person oversight. That is a genuine regulatory gap worth discussing, and the FDA has flagged concerns about compounded GLP-1 products precisely because quality and dosing consistency are not guaranteed the way they are with FDA-approved formulations.

But the 'bad for you' claim is where she goes off the rails. It is a vague, evidence-free assertion aimed at a large audience. The people most likely to be watching a 'one week Ozempic results' video are people actively considering or already using the medication. Telling them it will make them 'sicker and sicker' without any clinical basis is not skepticism. It is misinformation with a wellness aesthetic.

The 'lifelong customer' framing also oversimplifies. Weight regain after stopping semaglutide is well-documented (Wilding et al., 2022, Diabetes, Obesity and Metabolism), and that is a legitimate conversation about drug dependency versus chronic disease management. But implying malicious intent without evidence is a different thing entirely.

What should you actually know?

GLP-1 receptor agonists are not a perfect drug class, but they are not a scam either. The clinical picture is more complicated than either 'miracle shot' influencers or anti-pharma skeptics suggest.

Side effects are real and should be taken seriously. Nausea, vomiting, and GI distress affect a significant portion of users. Rare but serious risks including pancreatitis and thyroid C-cell tumors in rodent studies (with human risk still under evaluation) appear in the prescribing information for a reason. Muscle mass loss is a legitimate concern, particularly without adequate protein intake and resistance training.

On cost: the $500 a month figure she cites is roughly accurate for out-of-pocket brand-name pricing without insurance. That is a real access and equity issue. Compounded alternatives exist but carry their own risks around standardization and oversight.

The actual takeaway is this: if you are considering a GLP-1 medication, the decision should happen with a licensed clinician who knows your full health history, not based on a TikTok video from someone who was never on the drug in the first place.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jess · TikTok creator

69.9K views on this video

Replying to @babyface one week on ozempic results !!!

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found semaglutide users lost an average of 14.9% body weight versus 2.4% for placebo over 68 weeks in adults with obesity.

What does the video say about the select trial (lincoff et al., 2023, nejm) showed a?

The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major adverse cardiovascular events in people with obesity and existing cardiovascular disease on semaglutide.

What does the video say about weight regain after stopping semaglutide?

Weight regain after stopping semaglutide is well-documented, with one study showing two-thirds of lost weight returning within one year of discontinuation (Wilding et al., 2022, Diabetes, Obesity and Metabolism).

What does the video say about common side effects including nausea, vomiting, diarrhea,?

Common side effects including nausea, vomiting, diarrhea, and constipation affect a meaningful portion of GLP-1 users and are disclosed in FDA prescribing information.

What does the video say about compounded semaglutide?

Compounded semaglutide is not equivalent to FDA-approved Ozempic or Wegovy. The FDA has issued warnings about quality and dosing inconsistencies in compounded GLP-1 products.

What does the video say about the creator confirmed she never used ozempic, making her health?

The creator confirmed she never used Ozempic, making her health claims about the drug anecdotally baseless and her 'results' video deliberately misleading to 69,900 viewers.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jess, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.